Mucoadhesive micelles for delivery of drugs to the lung for the prophylactic treatment of COVID-19

用于向肺部输送药物以预防性治疗 COVID-19 的粘膜粘附胶束

基本信息

批准号：
552991-2020
负责人：
Sheardown, Heather
金额：
$ 3.64万
依托单位：
McMaster University
依托单位国家：
加拿大
项目类别：
Alliance Grants
财政年份：
2020
资助国家：
加拿大
起止时间：
2020-01-01 至 2021-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=704114
关键词：
Mucoadhesive micelles delivery drugs lung

项目摘要

The soaring death tolls from COVID-19 and the non-sustainability of the current economic situation pose an urgent worldwide need for an innovative solution to protect the public upon the anticipated restart of the economy. This project will focus on the development of a nasal spray formulation for post-exposure prophylaxis against COVID-19 which will help control the number of infections and, in turn, hasten the safe return of the public to normal life as well as being useful for control in the anticipated second wave. This proposal offers an innovative, straightforward and scalable prophylactic approach that can be self-administered by combining anti-viral drugs with proprietary and patented mucoadhesive micelles to provide a prolonged protective effect against infection. We will focus on the formulation of a nasal spray containing either hydroxychloroquine (HCQ) or a novel Angiopoietin-Tie2 inhibitor, which is proprietary to our partner Mannin Research Inc. Each drug will be incorporated into the patented mucoadhesive micelle delivery system from the Sheardown lab. These formulations will act as a prophylactic, either preventing entry of SARS-CoV-2, the virus responsible for COVID-19, into the respiratory tract or minimizing its impact and severity. They will then be developed for clinical use in partnership with Mannin.

COVID-19 造成的死亡人数飙升，以及当前经济形势的不可持续性，全世界迫切需要一种创新解决方案，以在经济预期重启时保护公众。该项目将重点开发用于 COVID-19 暴露后预防的鼻喷雾剂配方，这将有助于控制感染数量，进而加速公众安全恢复正常生活，并有助于控制在预期的第二波浪潮中。该提案提供了一种创新、直接和可扩展的预防方法，可以通过将抗病毒药物与专有和专利的粘膜粘附胶束相结合来自我管理，以提供针对感染的长期保护作用。我们将重点开发含有羟氯喹 (HCQ) 或新型血管生成素-Tie2 抑制剂的鼻喷雾剂配方，该抑制剂是我们的合作伙伴 Mannin Research Inc. 的专有产品。每种药物都将被纳入 Sheardown 实验室的专利粘膜粘附胶束递送系统中。这些制剂将起到预防作用，要么防止导致 COVID-19 的病毒 SARS-CoV-2 进入呼吸道，要么最大限度地减少其影响和严重程度。然后将与 Mannin 合作开发用于临床用途。